Hasil Pencarian  ::  Simpan CSV :: Kembali

"Pasien dengan kelainan bawaan pada rantai b-globin mungkin mengalami gejala penyakit yang lebih ringan jika mereka menghasilkan hemoglobin fetal (HbF) dengan kadar yang tinggi. Penggunaan hydroxyurea (HU) telah memperlihatkan peningkatan kadar HbF pada pasien penyakit ?sickle cell?, dan mungkin berguna pada b-talassemia. Kami memberi terapi HU kepada 13 pasien b-talassemia intermedia atau mayor, termasuk 6 pasien splenektomi. Pasien-pasien diberi dosis eskalasi (10 sampai 25 mg/kg/h) HU selama sekitar 2 tahun (median: 21 bulan, ?range?: 8 ? 55 bulan). Sebelas pasien menunjukkan respons kenaikan HbF pada pra-transfusi, masing-masing dari median awal 8,0% (2,5 - 61,3%) menjadi 28,0% (6,6 - 49,2%) dan 40,7% (4,8 - 72,3%) pada 3 bulan dan 18 bulan pasca terapi HU. Kenaikan yang sama pada nilai median Hb terlihat pada 1, 3 dan 18 bulan terapi HU. Enam dari 7 pasien yang tergantung transfusi yang menunjukkan kenaikan HbF (seorang dengan b-thalassemia mayor), juga memperlihatkan penurunan kebutuhan transfusi setelah dua tahun terapi HU. Respons terhadap HU juga terlihat dengan adanya pengecilan limpa. Selain ulkus di mulut yang menghilang dengan penurunan dosis HU, tidak terlihat toksisitas lain yang bermakna. Dapat disimpulkan bahwa pemberian HU pada pasien b-thalassemia menyebabkan peningkatan produksi HbF disertai perbaikan pada eritropoiesis, tanpa toksisitas yang bermakna. (Med J Indones 2007; 16:78-83).

---

Patients with severe inherited b-globin chain disorders may have milder illness if they produce high levels of fetal hemoglobin (HbF). Hydroxyurea (HU) has been shown to enhance HbF levels in patients with sickle cell disease and may be useful in b-thalassemias. We administered HU to 13 patients with b-thalassemia intermedia or major, including 6 splenectomized patients. The patients received escalating doses (10 to 25 mg/kg/d) of HU for around 2 years (median: 21 months, range: 8 - 55 months). Eleven patients responded with an increase in the pre-transfusion HbF levels, from a base line median of 8.0% (2.5 - 61.3%) to 28.0% (6.6 - 49.2%) and 40.7% (4.8 - 72.3%) at 3 months and 18 months post-HU, respectively. A concomitant increment in median hemoglobin levels was noted at 1, 3 and 18 months of HU therapy. Six of 7 transfusion-dependent patients who had an increment of HbF (one with b-thalassemia major) also had reduced transfusion requirement over the 2-year period of HU therapy. Response to HU was also shown by a reduction in spleen size. Apart from oral ulcers that resolved upon dose reduction of HU, no significant toxicity was noted. We conclude that increased HbF production in b-thalassemia patients, with an improvement in erythropoiesis, can be achieved using HU with minimal toxicity. (Med J Indones 2007; 16:78-83)."

"Thalassemia b mayor adalah penyakit yang disebabkan oleh kelainan sintesis rantai polipeptida b yang diturunkan secara otosom resesif. Pengobatan thalassemia b mayor pada umumnya berupa pemberian transfusi berulang, yang mengakibatkan penumpukan besi dan berakhir dengan hemokromatosis. Penumpukan besi dapat terjadi pada organ tubuh antara lain ginjal. Tujuan penelitian ini untuk mengetahui adanya gangguan fungsi ginjal pada penderita thalassemia b mayor berumur 15-28 tahun yang telah mendapatkan 6 unit packed red cells. Pada penelitian ini telah diperiksa kadar besi serum (SI) dan daya ikat besi total (TIBC) serta kadar mikroalbumin dan b2-mikroglobulin (b2-m) dalam urin. Hasil yang didapat 94,7% penderita menunjukkan peningkatan saturasi transferin dan 40% diantaranya disertai hemokromatosis; 73,4% disertai mikroalbuminuria, 1,3% dengan albuminuria dan 21,3% dengan peningkatan b2-m urin. Jumlah kasus dengan kelainan ginjal dijumpai pada 78,6%. (Med J Indones 2003; 12: 215-223)

---

b-thalassemia major is a disease caused by b polypeptide chain synthesis disorder which is inherited in an autosomal recessive manner from both parents and which is marked by little or no b-globin chain synthesis. Treatment for b-thalassemia major patients is by giving repeated blood transfusions, which causes iron accumulation, leading to hemochromatosis. Iron accumulation can occur in various body organ, including the kidneys. The aim of this study was to investigate the existence of renal impairment in b-thalassemia major patients. The subjects of this study were b-thalassemia major patients aged 15 - 28 years old who had received 6 units of packed red cells or more within 6 months. In this study, urine and serum samples of the subjects were taken and examined. Assay of serum iron was performed with Hitachi 737. Results were that 94.7% patients showed an increase in transferrin saturation and 40% of them had hemochromatosis; 73.4% had microalbuminuria; 1.3% had albuminuria and 21.3% had increased urinary b2-microglobulin (b2-m). A total of 78.6% of patients showed renal impairment. Conclusion of this study suggested that glomerular dysfunction happens in an earlier stage of the disease process. The high incidence of microalbuminuria is also attributed to defective ability of the proximal tubular cells to reabsorb protein besides dysfunction of the glomeruli. (Med J Indones 2003; 12: 215-223)"

"Di Indonesia, thalassemia mayor merupakan salah satu masalah kesehatan karena morbiditas dan mortalitasnya yang tinggi. Thalassemia mayor ditandai dengan anemia berat sejak usia anak-anak dan memerlukan transfusi teratur untuk mempertahankan kadar hemoglobin. Untuk mengurangi kebutuhan akan transfusi darah, dilakukan splenektomi. Trombosis merupakan salah satu komplikasi thalassemia yang banyak dilaporkan di berbagai negara, tetapi di Indonesia sampai saat ini belum ada laporan. Trombosit dan sistem koagulasi memegang peranan dalam patogenesis trombosis. Tujuan penelitian ini adalah untuk mendapatkan gambaran mengenai kelainan trombosit serta aktivasi koagulasi pada penderita thalassemia mayor yang sudah maupun yang belum di-splenektomi di Indonesia.Desain penelitian ini potong lintang. Subyek penelitian terdiri dari 31 orang penderita thalassemia mayor yang sudah displenektomi (kelompok splenektomi) dan 35 orang penderita thalassemia mayor yang belum mengalami splenektomi (kelompok nonsplenektomi). Untuk menilai fungsi trombosit, dilakukan pemeriksaan agregasi trombosit terhadap adenosin difosfat (ADP), aktivasi trombosit dinilai dengan mengukur kadar β-tromboglobulin (β-TG), sedangkan aktivasi koagulasi dinilai dengan pemeriksaan D-dimer.Hasil penelitian ini menunjukkan bahwa jumlah trombosit pada kelompok splenektomi Iebih tinggi secara bermakna dibandingkan kelompok non-splenektomi (549.260+251.662/μI vs 156.000/μl (kisaran 34.000-046.000/μl); p<0,001). Demikian pula agregasi trombosit terhadap ADP 1 pM maupun 10 pM Iebih tinggi secara bermakna pada kelompok splenektomi dibandingkan dengan kelompok non-splenektomi (1 pM: 17,3% (kisaran 1,9-104,0%) vs 5,2% (kisaran 0,5-18,2%); p <0,001 dan 10 pM: 91,2% (kisaran 27,3-136,8%) vs 55,93 + 17,27%; p<0,001). Kadar β-TG Iebih tinggi secara bermakna pada kelompok splenektomi dibandingkan kelompok non-splenektomi (178,81 + 86,3 IU/ml vs 100,11 + 40,0 IU/ml; p<0,001). Kadar D-dimer juga Iebih tinggi secara bermakna pada kelompok splenektomi dibandingkan non-splenektomi walaupun keduanya masih dalam rentang normal (0,2 μg/ml (kisaran 0,1-0,7 g/ml) vs 0,1 μg/ml (kisaran 0,1-0,8 μg/mI).Dari hasil penelitian ini, disimpulkan bahwa pada penderita thalassemia mayor di Indonesia terdapat jumlah trombosit dan fungsi agregasi yang bervariasi, sedangkan aktivasi trombosit meningkat, tetapi belum dapat dibuktikan adanya aktivasi koagulasi. Pada penderita thalassemia mayor yang sudah displenektomi didapatkan trombositosis, serta agregasi trombosit terhadap ADP dan aktivasi trombosit yang Iebih tinggi dibandingkan dengan penderita yang belum di-splenektomi.

---

Thalassemia major is one of the health problem in Indonesia due to its high morbidity and mortality. Thalassemia major is characterized by severe anemia presenting in the first years of life and requires regular transfusions to maintain hemoglobin level. Splenectomy is performed to decrease the need for transfusion. Thrombosis is one of the complications widely reported in patients with thalassemia in many parts of the world, but until now, there had been no report on this complication in Indonesia. Platelet and the coagulation system play a role in the pathogenesis of thrombosis. The aim of this study was to obtain the pattern of changes in platelet count, function and activation level, and activation of coagulation in patients with thalassemia major patients in Indonesia.The design of this study was cross-sectional. The subjects were 31 splenectomized and 35 non-splenectomized patients with thalassemia major. Platelet aggregation to adenosine diphosphate (ADP) was performed to assess platelet function; β-thromboglobulin level was used as marker of platelet activation, and D-dimer for activation of coagulation.The result of this study revealed a significantly higher platelet count in splenectomized compared to non-splenectomized patients (549.260 + 251.86210 vs-156.000/μl (34.000- 46.000/μl); p<0.001). Platelet aggregation to ADP were significantly higher in splenectomized patients than non-splenectomized group, both to 1 pM (17.3% (range 1.9-104M%) vs 5.2% (range 0.5-118.2%); p<0.001) and 10 μM ADP (91.2% (range 27.3-136.8%) vs 55.93 + 17.27%; p<0.001). β-thromboglobulin level was significantly higher in splenectomized patients compared to non-splenectomized patients (178.81 + 86.3 IU/rnl vs 100.11 + 40.0 IU/ml; p<0.001). D-dimer level was also significantly higher in the splenectomized group compared to non-splenectomized group although both had values within normal range (0.2 pglml (range 0.1-0.7 μg/mI) vs 0.1 pg1ml (range 0.1-0.8 μg/ml).We concluded that the platelet count and function were varied, while platelet activation level was increased in patients with thalassemia major in Indonesia, but activation of coagulation was not established. We also concluded that in splenectomized patients there were thrombocytosis and increased platelet aggregation to ADP and platelet activation level compared to non-splenectomized patients."

"Latar belakang: Thalassemia merupakan kelainan genetik yang paling banyak ditemukan di seluruh dunia. Penyakit ini dapat menimbulkan berbagai masalah dan kelainan berbagai organ tubuh, termasuk pada rongga mulut. Tujuan: memperoleh gambaran mengenai kelainan yang terjadi pada rongga mulut pasien thalassemia mayor di Pusat Thalassemia RSCM. Metode: Penelitian cross-sectional terhadap 76 pasien thalassemia mayor yang berusia diatas 12 tahun. Data didapat dengan melakukan pemeriksaan klinis dan wawancara terstruktur menggunakan panduan kuesioner. Hasil: Keluhan subyektif dalam rongga mulut yang sering dialami adalah: serostomia, diikuti dengan sariawan berulang, bibir mengelupas dan pecah-pecah, serta gusi berdarah. Prevalensi kelainan klinis yang ditemukan meliputi: inkompetensi bibir (25,0%); malokusi: klas I (40,79%), klas II (51,32%) dan klas III (3,95%); higiene oral buruk (67,11%), dan gingivitis (82,89%). Nilai rata-rata DMF-T adalah 4,97. Kondisi dan lesi patologik mukosa mulut yang paling banyak ditemukan adalah pigmentasi mukosa (69,74%), diikuti dengan depapilasi lidah (56,58%), mukosa ikterik (52,63%), cheilosis/cheilitis (50,0%), mukosa pucat (44,74%), erosi/deskuamasi mukosa (44,74%), stomatitis aftosa rekuren (15,79%), glositis defisiensi (14,47%) dan perdarahan gingiva (11,84%). Kesimpulan: Maloklusi, higiene oral buruk, gingivitis, serostomia, pigmentasi mukosa, depapilasi lidah, mukosa ikterik, dan cheilosis/cheilitis, merupakan masalah yang paling umum ditemukan pada pasien thalassemia mayor dalam penelitian ini, namun indeks karies gigi terlihat rendah.

---

Background: Thalassemia is the most common genetic disorders worldwide. The disease can cause various problems and disorders of various organs of the body, including in the oral cavity.

Objective: to describe the oral cavity disorders in patients with major thalassemia in Thalassemia Centre at Cipto Mangunkusumo Hospital.

Methods: cross-sectional study involved 76 patients with major thalassemia over 12 years of age. Data obtained by clinical examination and structured interviews using guidance from quistionnare.

Results: Oral subjective symptom which is often experienced is xerostomia, followed by recurrent aphthous stomatitis, cheilosis/cheilitis, and gingival bleeding. Prevalence of clinical findings consist of: incompetence of lips (25%); malocclusion: class I (40,79%), class II (51,32%) and class III (3,94%); poor oral hygiene (67,11), gingivitis (82,89%). DMF-T score was 4,97. Conditions and pathologic lesions more frequently seen are pigmentation of mucosa (69,74%), followed by depapillation of tongue (56,58%), icterus of mucosa (52,63%), cheilosis/cheilitis (50%), pallor of mucosa (44,74%), erosion/desquamation of mucosa (44,74%), recurrent aphthous stomatitis (15,79%), glossitis deficiency (14,47%), and gingival bleeding (11,84%).

Conclusion: Malocclusion, poor oral hygiene, gingivitis, xerostomia, pigmentation of mucosa, depapillation of tongue, icterus of mucosa, and cheilosis/cheilitis, were most prevalent problems in patients with major thalassemia in this study; nevertheless, dental caries show low index."

"Latar belakang dan tujuan: Thalassemia adalah penyakit anemia hemolitik yang diturunkan, merupakan penyakit genetik yang paling sering di dunia. Transfusi secara berkala pada pasien thalassemia dapat menyebabkan deposit besi pada berbagai organ seperti hipofisis. Deposit besi pada hipofisis dapat menyebabkan hipogonadotropik hipogonadisme. Biopsi merupakan pemeriksaan baku emas untuk menilai deposit besi pada organ, namun hal ini tidak dapat dilakukan pada hipofisis. Pemeriksaan MRI mulai digunakan unutuk mengukur kadar besi pada berbagai organ salah satunya hipofisis.Metode: Uji korelasi dengan pendekatan potong lintang untuk mengetahui nilai korelasi nilai MRI T2 dan T2 relaksometri serta SIR T2 hipofisis dengan kadar FSH dan LH pada pasien thalassemia mayor. Pemeriksaan dilakukan 28 subjek penelitian dalam kurun waktu Desember 2016 hingga Maret 2016.Hasil: Terdapat korelasi antara nilai relaksometri T2 hipofisis potongan koronal dengan kadar FSH dan LH, serta terdapat pula korelasi antara nilai SIR T2 hipofisis dengan kadar LH. Tidak terdapat korelasi antara nilai relaksometri T2 potongan koronal-sagital dengan kadar FSH dan LH, serta tidak terdapat pula korelasi antara SIR T2 hipofisis dengan kadar FSH.Kesimpulan: Nilai relaksometri T2 hipofisis potongan koronal dan SIR T2 hipofisis dapat digunakan sebagai acuan deposit besi pada hipofisis serta dapat memonitor terapi kelasi pada pasien thalassemia - mayor.

---

Background and abjective Thalassemia is a hereditary hemolytic anemia disorder, it is one of the most common genetic disease in the world. Periodic transfusion for thalassemia patients may lead to iron deposit in various organs such as pituitary gland. Iron deposit in pituitary gland may induce hypogonadotropic hypogonadism. Biopsy and histopathology assessment is the gold standard examination to assess organ iron deposit, however this method is inapplicable for pituitary gland. MRI examination has been started to be used for measurement of iron level in various organ, such as pituitary gland.

Method: This study uses cross sectional method. MRI T2 and T2 relaxometry value as well as SIR T2 of pituitary gland was correlated with FSH and LH level in patients with major thalassemia. This study involves 28 subjects and conducted from December 2016 to March 2017.

Result: There is a correlation between relaxometry values of T2 pituitary gland on coronal slice with the level of FSH dan LH. There is also a correlation between pituitary SIR T2 value with the level of LH. There are no correlation between relaxometry values of T2 on coronal sagittal slices with the level of FSH and LH, furthermore there are no correlation between pituitary SIR T2 with FSH level.

Conclusion: Relaxometry value of pituitary T2 on coronal slice and pituitary SIR T2 value may be use as reference for iron deposit on pituitary gland as well as to monitor chelating therapy in major thalassemia patients."

"ABSTRAKLatar belakang: Thalassemia merupakan kelainan genetik terbanyak di dunia, termasuk Indonesia. Pasien thalassemia mayor berisiko mengalami gangguan fungsi neurokognitif akibat anemia kronik dan penumpukan besi. Tujuan: mengetahui prevalens abnormalitas hasil EEG dan tes IQ, menganalisis faktor-faktor yang diduga berhubungan dengan gangguan fungsi neurokognitif pada anak dengan thalassemia mayor usia saat diagnosis, lama transfusi, pendidikan pasien, rerata Hb pra-transfusi, kadar feritin serum, saturasi transferin, dan komplians terhadap obat kelasi besi , serta untuk mengetahui apakah gangguan neurokognitif dapat memengaruhi fungsi sekolah. Metode: Penelitian potong lintang deskriptif analitik antara April 2016-April 2017. Pengukuran tes IQ menggunakan WISC-III. Hasil: Total subyek adalah 70 anak thalassemia mayor berusia antara 9 hingga 15,5 tahun. Prevalens hasil EEG abnormal adalah 60 dan prevalens skor IQ abnormal

---

ABSTRACTBackground Thalassemia is the most common hereditary disorders worldwide, including Indonesia. Chronic anemia and iron overload in thalassemia major lead to several risk factors including neurocognitive problems. Aim To investigate the prevalence of abnormal EEG and IQ test, to identify the factors related to neurocognitive function in children with thalassemia major age at diagnosis, years of transfusion, patients education, pre transfusion haemoglobin level, ferritin, transferrin saturation, and compliance to chelation , and to identify whether neurocognitive dysfunction affects child rsquo s school performance. Methods A cross sectional descriptive analitic study. Subjects were recruited from April 2016 April 2017. Cognitive function assessed by the WISC III. Results A total 70 children aged from 9 to 15.5 years old were recruited. The prevalence of abnormal EEG and abnormal IQ score "

"ABSTRAK Latar belakang. Kelasi besi diduga berperan terhadap penurunan fungsi ginjal pada pasien thalassemia mayor. Data fungsi ginjal pasien thalassemia mayor yang menggunakan kelasi besi oral di Jakarta masih terbatas. Tujuan. Mengetahui penurunan fungsi ginjal pasien thalassemia mayor yang mendapat kelasi besi oral dan faktor yang memengaruhinya. Metode penelitian. Penelitian dilakukan bulan Maret ndash; Juli 2017 pada pasien thalassemia mayor yang mendapat kelasi besi oral tunggal selama minimal 1 tahun. Fungsi ginjal dinilai dengan laju filtrasi glomerulus berdasarkan formula Schwartz revisi Fungsi tubulus ginjal dinilai dengan peningkatan rasio kalsium kreatinin urin hiperkalsiuria . Hasil penelitian. Total subjek sebanyak 54 orang 28 deferipron, 26 deferasiroks . Proporsi LFG menurun pada kelompok deferipron lebih tinggi dibandingkan deferasiroks 53,6 vs 46,2 . Hiperkalsiuria lebih banyak ditemukan pada kelompok deferasiroks dibandingkan deferipron 12,9 vs 3,6 . Penurunan LFG bermakna pada kelompok deferipron tetapi tidak bermakna pada kelompok deferasiroks. Tidak terdapat perbedaan bermakna LFG dan rasio kalsium kreatinin urin antara kelompok deferipron vs deferasiroks p=0,427; p=0,109 . Usia, hemoglobin, rerata hemoglobin, feritin, dosis kelasi besi dan saturasi transferin hanya memengaruhi fungsi tubular ginjal. Simpulan. Terdapat penurunan fungsi ginjal pada pasien thalassemia mayor yang mendapatkan kelasi besi oral. Fungsi ginjal pada thalassemia perlu dinilai berkala meski penurunannya tidak bermakna secara klinis.Kata kunci: Thalassemia, fungsi ginjal, kelasi besi oralABSTRACT Background. Iron chelator can cause renal dysfunction in thalassemia major patients. Data of renal function in thalassemia major patients who receive oral iron chelator are limited. Objective. To determine kidney dysfunction in thalassemia major patients receiving oral iron chelator and its correlating factors. Methods. The study was conducted in March ndash July 2017 on thalassemia major patients treated with single oral iron chelator for at least 1 year. Renal function determined by glomerular filtration rate measured with revised Schwartz formula. Tubular function determined by increased urine calcium creatinine ratio hypercalciuria . Results. Total subjects were 54 28 deferiprone, 26 deferasirox . Proportion of decreased GFR in deferipron group was higher than deferasirox 53,6 vs 46,2 . Hypercalciuria was higher in deferasirox group than deferiprone 12,9 vs 3.6 . Declining of GFR was significant in deferiprone group but not significant in deferasirox group. There was no significant difference of GFR and urinary creatinine calcium ratio in deferiprone vs deferasirox group p 0.427 p 0.109 . Age, hemoglobin level, mean hemoglobin, ferritin, iron chelator dose and transferrin saturation only affecting kidney tubular function. Conclusions. Renal dysfunction was found in thalassemia major patients receiving oral iron chelator. Kidney function in thalassemia major patients should be monitored periodically eventhough the decline was not significant. Keywords Thalassemia, renal function, oral iron chelator"

"Latar belakang. Kadar hemoglobin pre-transfusi dan feritin serum mempengaruhi pertumbuhan anak dengan thalassemia B-mayor. Penelitian tentang thalassemia sudah dilakukan di Indonesia, namun penelitian tentang hubungan thalassemia dengan pertumbuhan fisik masih terbatas. Tujuan. Mengetahui pengaruh kadar Hb pre-transfusi dan feritin serum berpengaruh terhadap pertumbuhan fisik pasien thalassemia ?-mayor. Metode. Dilakukan bulan Agustus-Oktober 2017 pada pasien anak dengan thalassemia B-mayor yang berobat ke Thalassemia-Centre RSUD Pekanbaru. Penelitian berupa analitik observasional potong lintang, menganalisis pengaruh kadar Hb pre-transfusi dan feritin serum terhadap parameter perawakan pendek dan sangat pendek, gizi kurang dan buruk, usia tulang yang terlambat. Hasil. Subjek 41 orang, rentang usia 18-204 bulan. Jenis kelamin laki-laki lebih banyak daripada perempuan 53,7 vs 46,3. 40 subjek mengalami retardasi pertumbuhan. Terdapat korelasi bermakna antara kadar Hb pre-transfusi dengan Z-score TB/U r=0,507, p=0,001 dan LILA/U r=0,467, p=0,02. Hb pre-transfusi berpengaruh terhadap interpretasi duduk/umur p=0,007, IK95 -1,5 - -0,3, subischial leg length/umur p=0,002, namun tidak pada interpretasi rasio segmen atas/bawah dan usia tulang. Hasil berbeda pada kadar feritin yang tidak memiliki korelasi terhadap semua variabel. Simpulan. Terdapat pengaruh yang bermakna secara statistik antara kadar Hb pre-transfusi dengan parameter penelitian serta tidak terdapat pengaruh yang bermakna secara statistik antara kadar feritin serum dengan parameter tersebut.

---

Background. The level of pre transfusion hemoglobin and ferritin serum affect physical growth on patient with thalassemic mayor. Study about thalassemia is mainly reported but its relationship with physical growth is limited.

Objective. The main objective of the present study was to evaluate the relationship of pre transfusion Hb and serum ferritin level in patient with thalassemic mayor.

Material and method. In this analytical cross sectional study, the growth parameters weight, standing height, sitting height, subischial leg length, nutritional status, bone age were measured in 41 patients attending Thalassemia Centre at RSUD in Pekanbaru from August October 2017.

Results. 41 patients with mean age 18 204 months. The results are boys dominated girls in sex criteria 53,7 vs 46,3. As much as 40 subjects have growth retardation. There rsquo s correlation in pre transfusion hemoglobin with Z score height for age r 0,507, p 0,001 and subischial length r 0,467, p 0,02. This study shows relationship in pre transfusion hemoglobin with sitting height p 0,007, IK95 1,5 0,3, subischial leg length p 0,002, but not in segment length and bone age. Serum ferritin level has no correlation to one of those parameters.

Conclusion. There is a significant relationship in physical growth based on parameters mentioned above with pre transfusion Hemoglobin, but not with serum ferritin level. "

"Talasemia merupakan kelainan genetik pembentukan rantai polipeptida globin yang mengakibatkan pembentukan hemoglobin tidak mencukupi kebutuhan sehingga harus dilakukan terapi transfusi darah secara teratur, khususnya bagi pasien talasemia mayor. Terapi transfusi darah dapat menyebabkan penimbunan besi dalam tubuh. Untuk mengatasinya, diperlukan agen kelator untuk mengikat dan mengeluarkan besi dari tubuh, salah satunya dengan menggunakan Deferoxamine. Oleh karena obat ini mahal dan memiliki beberapa efek samping, maka diperlukan terapi alternatif yang lebih murah dan aman, seperti menggunakan mangiferin yang terkandung dalam batang, daun, dan buah pohon mangga Mangifera indica L. Desain penelitian yang digunakan adalah studi eksperimental dengan menggunakan mangiferin dari ekstrak air daun Mangifera foetida L. yang dilarutkan dengan medium standar. Dari 24 sampel serum yang dipilih secara consecutive sampling hanya 7 sampel serum yang diolah datanya. Ke 7 sampel tersebut dibagi dalam empat kelompok perlakuan yaitu serum sebagai kontrol negatif, serum+mangiferin, serum+ Deferoxamine, dan serum+ekstrak dosis 0,75 mg. Selanjutnya, nilai absorban sampel diuji dengan spektrofotometer pada panjang gelombang 190-400 nm. Untuk menguji abnormalitas nilai absorban digunakan uji Kolmogorov-Smirnov. Sedangkan, untuk menguji hipotesis digunakan uji One Way Anova yang dilanjutkan dengan uji Post Hoc. Hasil uji One Way Anova menunjukkan bahwa ekstrak air daun Mangifera foetida L. dosis 0,75 mg memiliki efek kelasi terhadap feritin serum pasien talasemia (p=0,015). Sedangkan, hasil uji Post Hoc menunjukkan bahwa ekstrak air daun Mangifera foetida L. dosis 0,75 mg memiliki efek kelasi yang tidak sama dengan mangiferin/kontrol positif sebagai agen kelator terhadap feritin serum pasien talasemia (p=0,033).

---

Thalassaemia is a genetic disorder formation of globin polypeptide chain that resulted in the formation of hemoglobin are not sufficient and should be regular blood transfusion therapy, particularly for patients with thalassemia major. Blood transfusion therapy can lead to accumulation of iron in the body. Therefore, it’s needed a chelating agent to bind and remove iron from the body, one of them by using Deferoxamine. But, these drugs are expensive and have some side effects, that require alternative therapies that are cheaper and safer, such as using mangiferin contained in stems, leaves, and fruit of Mangifera indica L.

Research design is experimental study using mangiferin from aqueous extract of Mangifera foetida L. Leaf diluted with standard medium. From 24 serum samples selected by consecutive sampling, only 7 serum samples that is used in analysis data. The samples are divided into four intervension groups. They are serum as a negative control, serum+mangiferin, serum+Deferoxamine, and serum+0.75 mg dose of extract. Furthermore, the absorbent sample is tested by spectrophotometer at a wavelength of 190-400 nm. To test for normality data is used Kolmogorov-Smirnov. Meanwhile, to test the hypothesis is used One Way Anova followed by Post Hoc.

Result of One Way Anova showed that the aqueous extract of Mangifera foetida L. leaf 0.75 mg dose has a chelating effect of serum ferritin thalassemia patients (p = 0.015). Meanwhile, result of Post Hoc showed that the aqueous extract of Mangifera foetida L. leaf 0.75 mg dose does not have the same effect with mangiferin/positive control as a chelating agent of serum feritin thalassemia patients (p = 0.033)."

"Pengobatan talasemia berupa transfusi darah menyebabkan penumpukan besi di organ dan kerusakan sel. Pemberian deferoksamin sebagai kelator besi banyak menimbulkan efek samping dan mahal. Oleh karena itu, diperlukan pengobatan dengan bahan yang lebih aman dan terjangkau dengan memanfaatkan bahan alami yang memiliki efek kelasi besi. Ekstrak air daun Mangifera foetida memiliki efek kelasi terhadap feritin serum penderita talasemia, namun belum diteliti apakah ekstrak etanol daun M.foetida juga menunjukkan efek kelasi terhadap feritin. Studi eksperimental ini dilakukan pada serum pasien talasemia yang dibagi ke dalam tujuh perlakuan yaitu: serum, mangiferin, mangiferin ditambah serum, ekstrak etanol 0,5 mg dan 0,75 mg, ekstrak etanol 0,5 mg dan 0,75 mg ditambah serum, namun yang akan dianalisis hanya serum, mangiferin ditambah serum, ekstrak etanol 0,5 dan 0,75 mg ditambah serum. Nilai absorbansi diukur menggunakan spektrofotometer, λ = 280 nm. Uji one way anova menunjukkan ekstrak etanol M.foetida dosis 0,5 mg dan 0,75 mg memiliki efek kelasi dibandingkan kontrol negatif (p<0,001). Uji Post hoc menunjukkan ekstrak etanol M.foetida dosis 0,5 mg memiliki efek kelasi yang sama dengan dosis 0,75 mg (p=0,133). Ekstrak etanol daun M.foetida dosis 0,5 mg memiliki efek kelasi yang sama dengan mangiferin murni (p=0,52), sedangkan dosis 0,75 mg memiliki efek kelasi berbeda (p=0,001) yang mungkin disebabkan perbedaan dosis ekstrak etanol.

---

Treatment of thalassemia with blood transfusion causing iron accumulation in the organs and damaging cells. Chelating agent, deferoxamine causes side effects and expensive. Therefore, it?s needed a safer and cheaper treatment by utilizing natural ingredients which have chelating effect. Water extract of Mangifera foetida leaf has chelating effect on serum thalassemia patients, but there was no research the effects in the ethanol extract. The purpose of this study was to prove the effects of ethanol extract as a chelating agent. This study used an experimental study using seven serums of patients with thalassemia by ex vivo and devided into seven treatments: serum, mangiferin, mangiferin plus serum, etanol extract 0.5 mg and 0.75 mg, etanol extract 0.5 mg and 0.75 plus serum, however only four treatments will be analized: serum, mangiferin plus serum, etanol extract 0.5 mg and 0.75 mg plus serum. They were measured in a spectrophotometer with (λ)=280 nm. The result by One Way Anova statistical test showed that the ethanol extract of M. foetida leaf 0.5 mg and 0.75 mg has the chelating effect when it compared to negative control (p <0.001). Post hoc test showed that the ethanol extract 0.5 mg has the same chelating effect with ethanol extract 0,75 mg (p = 0.133). Ethanol extract 0.5 mg has the same effect of iron chelation with the mangiferin (p=0.52), while ethanol extract 0.75 mg has different effect (p=0.001). The differences of chelating effect maybe caused by the differences of extract dose."